Merck & Co., Inc., Rahway, N.J., USA Phase 3 Shows 43% Lower Risk of Progression/Death vs Chemo

What happened

Merck reported that its Phase 3 KEYNOTE-C93 trial met its primary endpoint in dMMR advanced or recurrent endometrial cancer. Pembrolizumab reduced the risk of progression or death by 43% versus platinum chemotherapy, with median progression-free survival of 38.2 months versus 8.4 months.

Confirmed

Global impact / market context

A large, statistically significant delay in disease progression could support wider use of pembrolizumab in gynecologic cancers. That may expand Merck's oncology revenue, while favorable safety versus chemotherapy could ease payer and guideline acceptance if regulators approve a new use.

Analyst inference

The result extends Merck's long-running growth story in immunotherapy beyond existing uses. Investors are weighing the commercial value of a potential new standalone indication against the still-uncertain overall survival benefit, which was positive in trend but not yet statistically significant.

Analyst inference

What to watch

1. Overall survival showed a positive trend with a hazard ratio of 0.77 but a p-value of 0.10, meaning the survival difference was not yet statistically significant and follow-up continues. Confirmed
2. Merck has said the results are intended for regulatory submission, which could enable a new monotherapy indication; watch whether a filing is actually made and what regulators decide. Proposed
3. Watch whether confirmatory overall survival becomes statistically significant; if it does, it would strengthen adoption, payer support and the commercial case for use in this cancer. Analyst inference

Evidence

• Original source link unavailable